| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive Chair | President & CEO
3 companies
Bertrand Loy is Executive Chair at ENTG and has filed Form 4s across 3 companies. Bertrand Loy's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $35.4M at current prices.
Historically, Bertrand Loy's trades have earned a middling insider score of 69/100 across 22 rated trades. Over a 12-month horizon, all 16 of those trades were profitable, with an average 12-month return of +21.2%.
The biggest single holding is ENTG (~$34.8M) as Executive Chair. The ENTG filings lean toward selling, a net 1,510,837 shares.
Bertrand Loy has 78 Form 4 filings on record from June 2015 to August 2026, across 4 companies: Director at ITT (ITT), 2026; Director at Ashland (ASH), 2026; Executive Chair at Entegris (ENTG), 2016–2026, and 1 more.
The 185 reported transactions were 64 open-market sales, 45 stock awards, 30 tax withholdings and 17 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 6 purchases worth about $392K and 14 sales worth about $158.2M.
The largest open-market purchase was 34,259 shares of HBIO at an average $3.05 on September 13, 2019, about $105K.
The largest open-market sale was 300,444 shares of ENTG at an average $120.69 on April 5, 2021, about $36.3M. Twelve months later ENTG was down 2%.
All 6 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | ENTG Entegris, Inc. | Executive Chair | Sale+OE10b5-1 | 44,138 | $144.41 | $6,373,968.58 | -16.2% | -7.8% | - | |
| Apr 14, 2026 | ENTG Entegris, Inc. | Executive Chair | Sale+OE10b5-1 | 17,396 | $140.22 | $2,439,267.12 | -7.1% | -0.9% | - | |
| Feb 25, 2026 | ENTG Entegris, Inc. | Executive Chair | Sale+OE10b5-1 | 109,838 | $138.25 | $15,185,007.99 | -33.5% | +3.5% | - | |
| Feb 2, 2026 | ENTG Entegris, Inc. | Executive Chair | Sale+OE10b5-1 | 65,250 | $119.61 | $7,804,351.46 | -17.6% | +16.3% | - | |
| Dec 1, 2025 | ENTG Entegris Inc | Executive Chair | Sale+OE10b5-1 | 57,570 | $76.88 | $4,425,994.50 | -15.8% | +77.6% | - | |
| Jul 3, 2024 | ENTG Entegris Inc | President & CEO | Sale+OE10b5-1 | 27,044 | $140.63 | $3,803,148.71 | -9.3% | -22.0% | -38.4% | |
| Aug 26, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 9,291 | $3.41 | $31,682.31 | +2.4% | -26.7% | +31.0% | |
| Aug 25, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 25,535 | $3.27 | $83,384.89 | +7.0% | -28.2% | +26.8% | |
| Aug 23, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 13,857 | $3.21 | $44,413.85 | +3.9% | -29.3% | +33.1% | |
| Aug 19, 2022 | HBIO Harvard Bioscience Inc | Director | Buy | 10,759 | $3.27 | $35,185.93 | +3.2% | -28.0% | +30.8% |